Advertisement

Clinical Drug Investigation

, Volume 38, Issue 7, pp 593–602 | Cite as

Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease

  • Annalisa Biffi
  • Lorenza Scotti
  • Federico Rea
  • Ersilia Lucenteforte
  • Alessandro Chinellato
  • Davide L. Vetrano
  • Cristiana Vitale
  • Nera Agabiti
  • Janet Sultana
  • Giuseppe Roberto
  • Alessandro Mugelli
  • Giovanni Corrao
  • on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE)
Original Research Article

Abstract

Background and Objective

Conflicting findings from studies evaluating the association between use of antidepressant drugs and mortality have been reported. We tested the hypothesis that better adherence to antidepressant therapy may reduce mortality.

Methods

The cohort included 29,845 individuals aged ≥ 65 years from several Italian health units who were newly treated with antidepressant drugs after hospital discharge with a diagnosis for cardiovascular disease during 2008–2010. These individuals were observed from the first prescription until the end of data availability (i.e. 2012–2014, depending on the local database). During this period, information on (1) prescription of antidepressants and other medications and (2) death from any cause (outcome) was recorded. Proportional hazards models were fitted to estimate the association between better adherence to antidepressants (defined as proportion of days covered ≥ 75%) and outcome, by adjusting and stratifying for several covariates.

Results

Patients with better adherence to antidepressants had a reduced mortality of 9% (95% CI 3–14). Patients who did not use other medicaments during follow-up had reduced mortality associated with better adherence to antidepressants of 21% (− 1–38), 14% (7–20), 20% (13–26) and 13% (7–19) for no users of antihypertensive agents, lipid-lowering agents, other cardiovascular drugs and antidiabetics, respectively.

Conclusions

Better adherence to antidepressants is associated with reduced all-cause mortality, mainly in patients who did not use other pharmacological treatments. Behavioural changes to enhance adherence among the elderly with cardiovascular disease might offer important benefits in reducing their mortality.

Notes

Acknowledgements

I-GrADE members: Nera Agabiti, Claudia Bartolini, Roberto Bernabei, Alessandra Bettiol, Stefano Bonassi, Achille Patrizio Caputi, Silvia Cascini, Alessandro Chinellato, Francesco Cipriani, Giovanni Corrao, Marina Davoli, Massimo Fini, Rosa Gini, Francesco Giorgianni, Ursula Kirchmayer, Francesco Lapi, Niccolò Lombardi, Ersilia Lucenteforte, Alessandro Mugelli, Graziano Onder, Federico Rea, Giuseppe Roberto, Chiara Sorge, Michele Tari, Gianluca Trifirò, Alfredo Vannacci, Davide Liborio Vetrano, Cristiana Vitale.

Compliance with ethical standards

Funding

This study was funded by a research grant from the AIFA—the Italian Medicines Agency—(AIFA, project AIFA-FARM9LBBBL), Rome, Italy. Data analyses were performed at the Laboratory of Healthcare Research & Pharmacoepidemiology, University of Milano-Bicocca with grants from the Italian Ministry of Education, University and Research (’Fondo d’Ateneo per la Ricerca’ portion, year 2015).

Conflicts of interests

EL received research support from the Italian Agency of Drug (AIFA). AM received research support from the Italian Agency of Drug (AIFA), the Italian Ministry for University and Research (MIUR), Gilead, and Menarini. In the last two years he received personal fees as speaker/consultant from Menarini Group, IBSA, Molteni, Angelini and Pfizer Alliance. GC received research support from the European Community (EC), the Italian Agency of Drug (AIFA), and the Italian Ministry for University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN and BMS). He also received honoraria as member of Advisory Board from Roche. AC received support for participation at pharmacological meetings (SIF) and honoraria as member of Advisory board on biological drugs. Other authors declare that they have no conflict of interest to disclose.

Supplementary material

40261_2018_642_MOESM1_ESM.pdf (17 kb)
Supplementary material 1 (PDF 16 kb)
40261_2018_642_MOESM2_ESM.pdf (21 kb)
Supplementary material 2 (PDF 21 kb)
40261_2018_642_MOESM3_ESM.pdf (263 kb)
Supplementary material 3 (PDF 263 kb)

References

  1. 1.
    Depression. A Global Public Health Concern. 2017. http://www.who.int/mental_health/. Accessed 28 Sep 2017.
  2. 2.
    Kingstone T, Burroughs H, Bartlam B, Ray M, Proctor J, Shepherd T, Bullock P, Chew-Graham CA. Developing a community-based psycho-social intervention with older people and third sector workers for anxiety and depression: a qualitative study. BMC Fam Pract. 2017;18:77.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic disease and decrements in health. Results from the world health surveys. Lancet. 2007;370:851–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Goldstein CM, Gathright EC, Garcia S. Relationship between depression and medication adherence in cardiovascular disease: the perfect challenge for the integrated care team. Patient Prefer Adherence. 2017;11:547–59.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Carney RM, Freedland KE. Depression in patients with coronary heart disease. Am J Med. 2008;121:S20–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Bambauer KZ, Adams AS, Zhang F, Minkoff N, Grande A, Weisblatt R, et al. Physician alerts to increase antidepressant adherence: fax or fiction? Arch Intern Med. 2006;166:498–504.CrossRefPubMedGoogle Scholar
  7. 7.
    Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9:91–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009;9:38.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200:137–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Scherrer JF, Garfield LD, Lustman PJ, Hauptman PJ, Chrusciel T, Zeringue A, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med. 2011;124:318–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA. 2001;286:1621–7.CrossRefPubMedGoogle Scholar
  13. 13.
    O’Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med. 2008;168:2232–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Brouwers C, Christensen SB, Damen NL, et al. Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression. Int J Cardiol. 2016;203:867–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167(4):367–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Diez-Quevedo C, Lupon J, Gonzalez B, et al. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol. 2013;167(4):1217–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman A, Shoval G. Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. Br J Psychiatry. 2015;206:297–301.CrossRefPubMedGoogle Scholar
  18. 18.
    Krivoy A, Stubbs B, Balicer RD, et al. Low adherence to antidepressants is associated with increased mortality following stroke: a large nationally representative cohort study. Eur Neuropsychopharmacol. 2017;27(10):970–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20.CrossRefPubMedGoogle Scholar
  20. 20.
    WHO Collaborating Centre for Drug Statistics Methodology. 2017. https://www.whocc.no/. Accessed 31 Aug 2017.
  21. 21.
    Corrao G, Ghirardi A, Segafredo G, Zambon A, Della Vedova G, Lapi F, et al. User-only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures. Pharmacoepidemiol Drug Saf. 2014;23:859–67.PubMedGoogle Scholar
  22. 22.
    Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168:329–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Haukka J, Arffman M, Partonen T, Sihvo S, Elovainio M, Tiihonen J, Lönnqvist J, Keskimäki I. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort. Eur J Clin Pharmacol. 2009;65:715–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medical adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Lapi F, Nicotra F, Scotti L, et al. Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol. 2012;74(3):536–44.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61:1234–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, Bernabei R, Landi F, SHELTER Project. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67:698–704.CrossRefPubMedGoogle Scholar
  28. 28.
    Zimmermann-Viehoff F, Kuehl LK, Danker-Hopfe H, Whooley MA, Otte C. Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the Heart and Soul Study. Psych Med. 2014;44:2975–84.CrossRefGoogle Scholar
  29. 29.
    Selim AJ, Fincke BG, Rogers WH, Qian S, Selim BJ, Kazis LE. Guideline recommended medications: variation across Medicare Advantage plans and associated mortality. J Manag Care Pharm. 2013;19:132–8.PubMedGoogle Scholar
  30. 30.
    Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26:546–50.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. pharmacoepidemiology. 3rd ed. Chichester: Wiley; 2000. p. 219–22.CrossRefGoogle Scholar
  33. 33.
    Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47:1039–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Corrao G, Mancia G. Generating evidence from computerized healthcare utilization databases. Hypertension. 2015;62:490–8.CrossRefGoogle Scholar
  35. 35.
    Arfe A, Nicotra F, Ghirardi A, et al. A probabilistic bias analysis for misclassified categorical exposures, with application to oral anti-hyperglycaemic drugs. Pharmacoepidemiol Drug Saf. 2016;25(12):1443–50.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Annalisa Biffi
    • 1
  • Lorenza Scotti
    • 1
  • Federico Rea
    • 1
  • Ersilia Lucenteforte
    • 2
  • Alessandro Chinellato
    • 3
  • Davide L. Vetrano
    • 4
    • 5
  • Cristiana Vitale
    • 6
  • Nera Agabiti
    • 7
  • Janet Sultana
    • 8
  • Giuseppe Roberto
    • 9
  • Alessandro Mugelli
    • 2
  • Giovanni Corrao
    • 1
  • on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE)
  1. 1.Laboratory of Healthcare Research and Pharmacoepidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative MethodsUniversity of Milano-BicoccaMilanItaly
  2. 2.Department of Neurosciences, PsychologyDrug Research and Children’s Health, University of FlorenceFlorenceItaly
  3. 3.Treviso Local Health UnitTrevisoItaly
  4. 4.Department of Geriatrics, Neurosciences and Orthopaedics, A. Gemelli University HospitalUniversità Cattolica del Sacro CuoreRomeItaly
  5. 5.Aging Research Center, Department of Neurobiology, Health Care Sciences and SocietyKarolinska Institutet and Stockholm UniversityStockholmSweden
  6. 6.Department of Medical SciencesIRCCS San Raffaele PisanaRomeItaly
  7. 7.Department of EpidemiologyLazio Regional Health ServiceRomaItaly
  8. 8.Department of Biomedical and Dental Sciences and Morphofunctional ImagingUniversity of MessinaMessinaItaly
  9. 9.Epidemiology UnitRegional Agency for Healthcare Services of TuscanyFlorenceItaly

Personalised recommendations